Hoth Therapeutics Reports Data For HT-001 In Treating EGFRI-Associated Papulopustular Eruptions, With Cancer Patient Successfully Ceasing Treatment After One Week Due To Rapid Symptom Resolution
Author: Benzinga Newsdesk | September 05, 2024 08:22am